MYOSIN THERAPEUTICS INC

Myosin Therapeutics is a clinical-stage biotechnology company based in Jupiter, Florida, developing first-in-class therapies that target molecular nanomotors — specifically members of the myosin family of motor proteins. Spun out of The Herbert Wertheim UF Scripps Institute, the company was founded on the discovery that non-muscle myosin II (NMII) plays a critical role in tumor progression and dysregulated brain plasticity, making it a novel druggable target. Their lead program, MT-125, targets NMII in glioblastoma (GBM) and has received FDA Fast Track Designation, Orphan Drug Designation, and IND clearance, with a Phase 1/2 STAR-GBM trial initiated in May 2026. A second program, MT-110, targets NMII for methamphetamine use disorder and CNS indications. The company has secured significant non-dilutive funding through NIH SBIR/STTR programs and the Florida Cancer Innovation Fund, supplemented by two seed funding rounds.